Sunday 18 October 2026
Export AVIR’s income statement to Excel — free account
Atea Pharmaceuticals, Inc.
AVIR Healthcare Biotechnology
In the quarter to June 2026, EPS grew 6.82% and free cash flow grew 85.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
4.32
0.21
−4.64%
Follow AVIR
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
7.80 | 7.67 | 7.59 | 16.32 | |
Current Ratio |
8.13 | 7.89 | 7.82 | 16.66 | |
Net Debt/EBITDA |
6.18 | 5.28 | 5.42 | 7.08 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.13 | 1.02 | 0.63 | 0.96 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.46) | (0.59) | (0.35) | (0.51) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.46) | (0.59) | (0.35) | (0.51) | |
Cash per Share |
2.74 | 3.23 | 3.70 | 4.17 | |
Shareholders Equity per Share |
2.55 | 2.95 | 3.38 | 3.99 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.55 | 2.95 | 3.38 | 3.99 | |
Free Cash Flow |
(37.08) | (46.39) | (28.22) | (40.37) | |
Working Capital |
200.54 | 229.83 | 271.21 | 315.96 | |
Net Current Asset Value |
200.54 | 229.83 | 271.21 | 308.96 | |
| Other line items | |||||
Average Payables |
9.45 | 8.42 | 8.70 | 4.65 | |
Average Assets |
311.94 | 353.52 | 389.94 | 416.96 | |
Average Common Equity |
284.29 | 322.40 | 357.15 | 387.15 |
Columns are period end dates